Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

r of this year.
  • Improved the balance sheet by retiring $17.0 million out of the total $22.0 million principle amount of outstanding convertible notes. These notes carried a coupon rate of 4.75% payable semi-annually and had a maturity date of July 15, 2009. Under the terms of the early retirement, Novavax paid 70% of the principal plus accrued and unpaid interest, or $12.1 million, in cash and issued 2,040,000 shares of its common stock for the remaining 30% of the principal, valued in the transaction as approximately $5.1 million. The remaining $5.0 million in outstanding convertible notes will be due on July 15, 2009 and can be paid up to 50% in stock at maturity at Novavax's option.
  • Increased liquidity by raising $11.0 million from sale of 12.5 million shares of common stock to a wholly owned subsidiary of Cadila Pharmaceuticals and raising approximately $7.5 million from the sale of approximately 3.1 million shares of common stock under the sales agreement with Wm Smith & Co.

  • "We are pleased with the significant clinical, corporate, and financial progress we have made in the past few months," said Dr. Rahul Singhvi, Novavax's President and Chief Executive Officer. "We have made substantial progress in advancing our VLP based influenza vaccines over the past three years. The recent emergence of the novel influenza A (H1N1) virus highlights the potential value of our recombinant VLP technology as we can produce a genetically matched vaccine to the outbreak strain in about half the time of traditional vaccine technologies. We are in communication with governments and health authorities around the world and will help in any way possible. With the improvement in our financial position, we are in a much stronger position to continue development of our vaccine pipeline and pursue partnerships."

    The anticipated milestones for the remainder of 2009 include:

    <
    '/>"/>
    SOURCE Novavax, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
    2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
    3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
    4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
    5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
    6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
    7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
    8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
    9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
    10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
    11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/26/2014)... Albany, NY (PRWEB) July 26, 2014 ... 2020 provides key market data on the Canada ... in millions of US dollars, volume (in units) ... segments - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy ... Browse Full Report at http://www.marketresearchreports.biz/analysis/213254 . , ...
    (Date:7/25/2014)... July 26, 2014 "Ischemic Stroke ... 2014" provides data on the Ischemic Stroke and ... elemental information and data relating to the clinical ... View full global Ischemic Stroke Research Report 2014 ... overview of the trial numbers and their recruitment ...
    (Date:7/25/2014)... THOUSAND OAKS, Calif. , July 25, 2014 /PRNewswire/ ... its Board of Directors today declared a $0.61 per ... dividend will be paid on Sept. 5, 2014, to ... business on Aug. 14, 2014.  About ... biology for patients suffering from serious illnesses by discovering, ...
    (Date:7/25/2014)... live in each person,s digestive tract. Scientists believe that ... off harmful infections, but their role in human health ... on the role of these bacteria, a team of ... tracked fluctuations in the bacterial populations of two research ... the July 25 issue of the journal Genome ...
    Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
    ... December 2 NicOx S.A.,(NYSE Euronext Paris: ... agreement with,DSM for the commercial manufacture and ... pharmaceutical ingredient). Naproxcinod is NicOx, lead,investigational product ... Oxide-Donating (CINOD) class of,anti-inflammatory agents, which recently ...
    ... (Pink Sheets: CGCP), a leading developer of surgical products used ... announced the addition of veteran medical device executive and an ... of the Company,s Board of Directors, increasing the number of ... Mr. Cohen, 49, has over 25 years of executive ...
    ... SHANGHAI, China, Dec. 2 /PRNewswire-Asia/ -- WuXi PharmaTech ... pharmaceutical, biotechnology and medical device,research and development outsourcing ... today announced it will dedicate its Philadelphia facility ... cell therapy,services, and as of December 31, 2008, ...
    Cached Biology Technology:NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 2Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 3WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 2WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 3WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 4WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 5
    (Date:7/27/2014)... revealed that nicotine and cotinine, a metabolite of nicotine, ... carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK ... ultimately ends up in the tobacco smoke. Once inhaled, ... it is activated by a variety of enzymes called ... that nicotine can partially interfere with the activation of ...
    (Date:7/27/2014)... strike that wiped them out if it had taken ... , A fresh study using up-to-date fossil records and ... new narrative of the prehistoric creatures, demise, some 66 ... few million years before a 10km-wide asteroid struck what ... included extensive volcanic activity, changing sea levels and varying ...
    (Date:7/27/2014)... the largest prevalence studies to date, researchers from the ... for the hepatitis C virus (HCV). Findings published in ... Study of Liver Diseases, indicate that genotype 1 is ... infected of which one-third reside in East Asia. Genotype ... next most prevalent, followed by genotypes 2, 4, 6, ...
    Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Dinosaurs fell victim to perfect storm of events, study shows 2Hepatitis C virus genotype 1 is most prevalent worldwide 2
    ... How,s this for precision? Researchers with the University of ... knock single atoms off a silicon wafer without disturbing ... engineering professor Vince Donnelly and Demetre Economou, Hugh Roy ... same department, are supported in this project by an ...
    ... to share knowledge, projects and developments in ... creation of synergies and possible frameworks for ... and institutions that address this matter. ... and will be open untill November 11th., ...
    ... at the National Science Foundation (NSF)--working cooperatively with ... field science supported by the U.S. Antarctic Program, ... to the maximum extent possible, following the October ... a Presidential mandate to manage the U.S. Antarctic ...
    Cached Biology News:Creating smaller, and more powerful, integrated circuits 2NSF, US Antarctic Program partners, working to restore Antarctic research season to the maximum extent possible 2NSF, US Antarctic Program partners, working to restore Antarctic research season to the maximum extent possible 3
    ... 384, compatible with hood ... handling system for 384-well ... accurately prepares large quantities ... The Wellpro also performs ...
    MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
    ... has been determined, the challenge is to ... audience of scientists, educators and students. Current ... over the Internet, either via online journals ... literature has the advantage of wide acceptance ...
    ... 45° Fixed Angle rotor for ... CL2, Centra CL3/CL3R, HN-SII or ... style rotor accepts 15 mL ... disposable conical tubes as well ...
    Biology Products: